Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Boehringer Academy

- PMLiVE

Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia

The deals aim to accelerate drug development in oncology, neurology and immunology

- PMLiVE

NIHR awards £2.3m for AI study to improve radiotherapy for lung cancer

The AI tool is expected to help doctors plan each patient’s radiotherapy treatment

- PMLiVE

Boehringer and Lilly’s Jardiance granted MHRA approval to treat chronic kidney disease

Approximately 7.2 million people in the UK are affected by the long-term kidney condition

The secret nobody told you about how to go viral

How to create content people actually want to read and share online

Page & Page and Partners

- PMLiVE

Vironix and Oxford University partner to advance chronic kidney disease monitoring

The partners will aim to develop learning models that predict the progression of CKD

- PMLiVE

Study shows AI scans could detect Parkinson’s years before clinical presentation

OCT scans could be used by the NHS for the diagnosis of neurodegenerative diseases

- PMLiVE

Boehringer sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for selected medicines

- PMLiVE

NICE recommends AI technologies for radiotherapy treatment planning

AI technology could provide the NHS with significant time and cost benefits

- PMLiVE

AI-supported mammography screening shows promise in breast cancer detection

The AI-supported screening tool detected cancer in 244 people in the study

AI in healthcare communication, today and tomorrow.

Advances in AI technology have meant that agencies can now provide genuine utility to healthcare communications.

Page & Page and Partners

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links